Clinical Trial Detail

NCT ID NCT02701673
Title Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

Burkitt lymphoma

diffuse large B-cell lymphoma

non-Hodgkin lymphoma

Hodgkin's lymphoma

Therapies

Azacitidine

Pyridoxine

Gemcitabine

Belinostat

Busulfan

Melphalan

Age Groups: child adult

No variant requirements are available.